The company expects to diagnose patients with a medical condition -pain and inflammation of the knee-osteoarthritis.
In this study, Ampion is injected into the knees of patients with osteoarthritis of the knee in combination with standard therapy, including steroids, aiming to demonstrate a reduction in pain and improved range of motion compared to placebo.
The study drug is planned to alleviate and confirm the hypothesis that the current outcome benefit is compatible with the mechanism of action of the drug.